162 related articles for article (PubMed ID: 36520173)
1. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer.
Çağlayan D; Koçak MZ; Geredeli Ç; Tatlı AM; Göksu SS; Eryılmaz MK; Araz M; Artaç M
Eur J Clin Pharmacol; 2023 Feb; 79(2):243-248. PubMed ID: 36520173
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Eser K; Önder AH; Sezer E; Çil T; İnal A; Öztürk B; Erçolak V; Duman BB; Çelik H; Köşeci T; Kesen O
BMC Cancer; 2022 May; 22(1):516. PubMed ID: 35525929
[TBL] [Abstract][Full Text] [Related]
3. Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
Odabas H; Dogan A; Ozcelik M; Yildirim S; Ozkerim U; Turan N; Yildirim ME; Gumus M
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984558
[No Abstract] [Full Text] [Related]
4. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
Del Re M; Crucitta S; Omarini C; Bargagna I; Mongillo M; Palleschi M; Stucci S; Meattini I; D'Onofrio R; Lorenzini G; Biondani P; De Giorgi U; Porta C; Livi L; Natalizio S; Fontana A; Giontella E; Angelini L; Fogli S; Danesi R
Breast; 2022 Dec; 66():157-161. PubMed ID: 36283134
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer.
Lee JE; Kwon SH; Kwon S; Jung HI; Nam JH; Lee EK
JAMA Netw Open; 2023 Jul; 6(7):e2324852. PubMed ID: 37477917
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M; Omarini C; Diodati L; Palleschi M; Meattini I; Crucitta S; Lorenzini G; Isca C; Fontana A; Livi L; Piacentini F; Fogli S; De Giorgi U; Danesi R
ESMO Open; 2021 Oct; 6(5):100231. PubMed ID: 34509802
[TBL] [Abstract][Full Text] [Related]
7. The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Chang YC; Song J; Chang Y; Huang CH; Sudan A; Chen PC; Chi KY
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958308
[TBL] [Abstract][Full Text] [Related]
8. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.
Guliyev M; Şen GA; Gültürk İ; Majidova N; Akdağ G; Ahadzade A; Turna H; Demirci NS
Breast Cancer Res Treat; 2024 Jun; 205(3):633-640. PubMed ID: 38526689
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Yıldırım HÇ; Kutlu Y; Mutlu E; Aykan MB; Korkmaz M; Yalçın S; Şakalar T; Celayir ÖM; Kayıkçıoğlu E; Aslan F; Hafızoğlu E; Altıntaş YE; Keskinkılıç M; Chalabiyev E; Çelebi A; Dursun B; Kapar C; Özen M; Acar Ö; Dülgar Ö; Kut E; Biter S; Kus F; Almuradova E; Erdoğan AP; Saray S; Güven DC; Şimşek ET; Üskent N; Kemal Y; Çakar B; Açıkgöz Ö; Kılıçkap S; Aksoy S
Int J Clin Oncol; 2024 Mar; 29(3):258-265. PubMed ID: 38310597
[TBL] [Abstract][Full Text] [Related]
11. Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
Takahashi K; Uozumi R; Mukohara T; Hayashida T; Iwabe M; Iihara H; Kusuhara-Mamishin K; Kitagawa Y; Tsuchiya M; Kitahora M; Nagayama A; Kosaka S; Asano-Niwa Y; Seki T; Ohnuki K; Suzuki A; Ono F; Futamura M; Kawazoe H; Nakamura T
Oncologist; 2024 Jun; 29(6):e741-e749. PubMed ID: 38340010
[TBL] [Abstract][Full Text] [Related]
12. Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer.
Schieber T; Steele S; Collins S; Berger M; Fleming M; McLaughlin E; Sudheendra P; Vargo C
Clin Breast Cancer; 2023 Aug; 23(6):658-663. PubMed ID: 37296062
[TBL] [Abstract][Full Text] [Related]
13. Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis.
de Moraes FCA; Pereira CRM; Sano VKT; Laia EA; Stecca C; Burbano RMR
Front Pharmacol; 2024; 15():1352224. PubMed ID: 38769999
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
Yıldırım HÇ; Mutlu E; Chalabiyev E; Özen M; Keskinkılıç M; Ön S; Çelebi A; Dursun B; Acar Ö; Kahraman S; Aykan MB; Kaman Ö; Doğan A; Erdoğan AP; Melisa Celayir Ö; Günenç D; Güven DC; Vedat Bayoğlu İ; Yavuzşen T; Hacıbekiroğlu İ; İnanç M; Kılıçkap S; Yalçın Ş; Aksoy S
Breast; 2022 Dec; 66():85-88. PubMed ID: 36208540
[TBL] [Abstract][Full Text] [Related]
15. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
17. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Hecht KA; Selby C
Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
[TBL] [Abstract][Full Text] [Related]
18. The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Uğraklı M; Koçak MZ; Dinç G; Genç TB; Çağlayan M; Uğraklı S; Hendem E; Er MM; Çağlayan D; Eryılmaz MK; Araz M; Geredeli Ç; Tatlı AM; Eren OÖ; Artaç M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9183-9189. PubMed ID: 37184681
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
García-Trevijano Cabetas M; Lucena Martínez P; Jiménez Nácher I; Díaz Almirón M; Zamora Auñón P; Herrero Ambrosio A
Int J Clin Pharm; 2021 Aug; 43(4):893-899. PubMed ID: 33170404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
